Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-07-01 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司关于持股5%以上股东股份协议转让完成过户登记的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of share transfer registration for a shareholder holding more than 5% of the company's shares. It details the transfer agreement, the number of shares transferred, the price, and the updated shareholding structure. It explicitly mentions that the transfer does not affect control of the company and complies with relevant laws and regulations. There is no financial report, earnings data, or management discussion. The document is a formal notification of a major shareholding change, fitting the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming this classification.
2024-07-01 Chinese
辰欣药业股份有限公司关于使用闲置的募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the progress of using idle raised funds for cash management, specifically investing in bank wealth management products. It includes information about the investment amount, product details, risk control measures, decision-making procedures, and financial impact. The document is not a full financial report but an update on financing activities related to the use of raised funds. It does not contain comprehensive financial statements or quarterly/yearly financial results. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2024-07-01 Chinese
辰欣药业股份有限公司关于控股股东股份解除质押的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the total pledged shares before and after the release, and the proportion of shares pledged relative to total shareholding and company capital. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Transaction in Own Shares (POS) as it relates to changes in share pledging by insiders or controlling shareholders.
2024-07-01 Chinese
辰欣药业股份有限公司2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual dividend distribution by the company 辰欣药业股份有限公司. It details the dividend per share, relevant dates for dividend distribution, the shareholder meeting approval date, tax withholding information, and instructions for dividend payment. The document is not a full annual report or financial statement but a specific announcement about dividend amounts and payment logistics following shareholder approval. This fits the definition of a Notice of Dividend Amount (DIV). The document length is 3553 characters, which is consistent with a detailed dividend announcement rather than a full report.
2024-06-20 Chinese
恒泰长财证券有限责任公司关于辰欣药业股份有限公司2023年度差异化分红事项的核查意见
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a detailed independent financial advisor's verification opinion regarding a differentiated dividend distribution matter for the company 辰欣药业股份有限公司. It discusses the background, legal basis, specific dividend distribution plan, and the calculation of ex-dividend prices related to the 2023 fiscal year profit distribution. The document includes financial figures such as net profit, dividend per share, and total shares involved. It is not a brief announcement but a substantive report with financial data and analysis related to profit distribution and share repurchase impacts. The content is focused on dividend distribution details and compliance verification rather than just announcing results or voting outcomes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) because it relates to the implementation and verification of a profit distribution plan approved at the annual shareholders meeting, including the impact on shareholders' rights and dividend payments. However, since it is more of a verification opinion on the dividend distribution rather than the voting results themselves, and it contains detailed financial data about the dividend distribution plan, it aligns closely with DVA rather than a simple announcement (RPA) or regulatory filing (RNS). The document length is under 5,000 characters but contains substantive financial and legal analysis, so it is not just an announcement. Hence, the best classification is DVA with high confidence.
2024-06-20 Chinese
辰欣药业股份有限公司关于持股5%以上股东内部协议转让股份暨股东权益变动的进展公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the internal agreement transfer of shares among shareholders holding more than 5% of the company's stock, detailing changes in shareholding percentages and related corporate registration updates. It does not contain financial statements, earnings data, or detailed management discussion. It is a regulatory announcement about changes in major shareholdings and shareholder rights. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming this classification.
2024-06-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.